Syndax Pharmaceuticals's top three insider shareholders as of March 23, 2026 are Michael A Metzger (Chief Executive Officer, 491.69K shares), Dennis Podlesak (Director, 239.76K shares), Keith A. Goldan (Chief Financial Officer, 140.43K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Michael A Metzger | Chief Executive Officer | 491,690 | 0 | 10 Feb, 2026 |
| Dennis Podlesak | 239,763 | 0 | 06 Feb, 2026 | |
| Keith A. Goldan | Chief Financial Officer | 140,429 | 0 | 10 Feb, 2026 |
| Keith Katkin | 124,000 | 0 | 06 Feb, 2026 | |
| Jennifer Jarrett | 114,000 | 0 | 06 Feb, 2026 | |
| Pierre Legault | 114,000 | 0 | 06 Feb, 2026 | |
| Martin H. Jr. Huber | 103,000 | 0 | 06 Feb, 2026 | |
| Nicholas A.J. Botwood | Head Of Rd, Cmo | 95,165 | 0 | 06 Feb, 2026 |
| William Meury | 90,000 | 0 | 07 Feb, 2025 | |
| Neil Gallagher | President, Head Of Rd | 85,095 | 0 | 12 Feb, 2025 |
| Aleksandra Rizo | 49,000 | 0 | 06 Feb, 2026 | |
| Briggs Morrison | 34,836 | 0 | 09 Feb, 2024 | |
| Fabrice Egros | 32,000 | 0 | 03 Feb, 2022 | |
| Michael L. Meyers | Svp, Chief Medical Officer | 23,280 | 0 | 03 Feb, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Feb, 2026 | Keith A. Goldan | Common Stock | D | 3,410 | $21.03 | 140,429 | D | S |
| 09 Feb, 2026 | Michael A Metzger | Common Stock | D | 17,159 | $21.03 | 491,690 | D | S |
| 04 Feb, 2026 | Aleksandra Rizo | Common Stock | A | 24,000 | $0.00 | 49,000 | D | A |
| 04 Feb, 2026 | Nicholas A.J. Botwood | Common Stock | A | 24,000 | $0.00 | 59,165 | D | A |
| 04 Feb, 2026 | Dennis Podlesak | Common Stock | A | 48,000 | $0.00 | 239,763 | D | A |
| 30 Jan, 2026 | Keith A. Goldan | Common Stock | A | 1,219 | $8.48 | 93,671 | D | J |
| 04 Feb, 2026 | Jennifer Jarrett | Common Stock | A | 24,000 | $0.00 | 114,000 | D | A |
| 04 Feb, 2026 | Keith Katkin | Common Stock | A | 24,000 | $0.00 | 124,000 | D | A |
| 04 Feb, 2026 | Martin H. Jr. Huber | Common Stock | A | 24,000 | $0.00 | 103,000 | D | A |
| 04 Feb, 2026 | Michael A Metzger | Common Stock | A | 73,000 | $0.00 | 371,661 | D | A |
| 04 Feb, 2026 | Pierre Legault | Common Stock | A | 24,000 | $0.00 | 114,000 | D | A |
| 04 Feb, 2026 | Nicholas A.J. Botwood | Common Stock | A | 36,000 | $0.00 | 95,165 | D | A |
| 04 Feb, 2026 | Keith A. Goldan | Common Stock | A | 21,500 | $0.00 | 115,171 | D | A |
| 04 Feb, 2026 | Michael A Metzger | Common Stock | A | 144,600 | $0.00 | 516,261 | D | A |
| 04 Feb, 2026 | Keith A. Goldan | Common Stock | A | 30,750 | $0.00 | 145,921 | D | A |
| 06 Feb, 2026 | Michael A Metzger | Common Stock | D | 7,412 | $20.62 | 508,849 | D | S |
| 04 Feb, 2026 | Nicholas A.J. Botwood | Stock Options (Right to buy) | A | 144,700 | $20.43 | 144,700 | D | A |
| 04 Feb, 2026 | Michael A Metzger | Stock Options (Right to buy) | A | 440,000 | $20.43 | 440,000 | D | A |
| 06 Feb, 2026 | Keith A. Goldan | Common Stock | D | 2,082 | $20.62 | 143,839 | D | S |
| 04 Feb, 2026 | Keith A. Goldan | Stock Options (Right to buy) | A | 118,000 | $20.43 | 118,000 | D | A |